SYSMEX DEVELOPS TECHNOLOGY TO DIAGNOSE THE RISK OF POSTOPERATIVE RECURRENCE OF EARLY-STAGE CANCER

Sysmex announced the development of a new technology based on a cell cycle profiling for diagnosis of the risk of recurrence in patients with early-stage cancer. In a clinical study of roughly 200 cases conducted in collaboration with Shinzaburo Noguchi, Graduate School of Medicine, Osaka University, this technology was found to be a high degree of clinical usefulness in patients with early stages of breast cancer.

Japan Corporate News (http://japancorp.net/Article.Asp?Art_ID=9176)